Увійти

Готові списки джерел за темами / Systemic lupus erythematosus Immunological aspects / Книги

Щоб переглянути інші типи публікацій з цієї теми, перейдіть за посиланням: Systemic lupus erythematosus Immunological aspects.

Книги з теми "Systemic lupus erythematosus Immunological aspects"

Автор: Grafiati

Опубліковано: 4 червня 2021

Оновлено: 12 лютого 2022

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся з топ-35 книг для дослідження на тему "Systemic lupus erythematosus Immunological aspects".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Переглядайте книги для різних дисциплін та оформлюйте правильно вашу бібліографію.

1

Coping with lupus: A guide to living with lupus for you and your family. Garden City Park, N.Y: Avery Pub. Group, 1991.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Liling, Chen, and Li Jiaxiong, eds. Hong ban xing lang chuang shi pu. Taibei Shi: Er yu wen hua shi ye you xian gong si, 2003.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Permut, Joanna Baumer. Embracing the wolf: A lupus victim and her family learn to live with chronic disease. Atlanta, Ga: Cherokee Pub. Co., 1989.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Sheerin, Fintan. Systemic lupus erythematosus: The wolf among the lambs : a comprehensive study of all aspects of the disease, and of the nursing care required by one patient. Dublin: The author, 1991.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Flannery O'Connor and Teilhard de Chardin: A journey together towards hope and understanding about life. New York: Peter Lang, 2009.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

6

1933-, Voss Edward W., ed. Anti-DNA antibodies in SLE. Boca Raton, Fla: CRC Press, 1988.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Berden, Jo H. M., and Jack F. M. Wetzels. Immunological investigation of the patient with renal disease. Edited by Christopher G. Winearls. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199592548.003.0017.

Повний текст джерела

Анотація:

Laboratory techniques (electrophoresis, indirect immunofluorescence, ELISA, and immunoblotting) required for immunological investigation of the patient with renal disease are described. Renal disease-related aspects of immunoglobulins (immunoglobulin A, paraproteins, cryoglobulins), complement, antinuclear antibodies, anti-C1q antibodies, antineutrophil cytoplasmic antibodies, anti-glomerular basement membrane antibodies, antipodocyte antibodies, antiphospholipid antibodies, and antimicrobial responses (streptococci, hepatitis C, hepatitis B) are reviewed. Laboratory assays which evaluate the

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Murphy, Claire Louise, Yiannis Ioannou, and Nicola Ambrose. Juvenile systemic lupus erythematosus. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198739180.003.0008.

Повний текст джерела

Анотація:

Juvenile-onset systemic lupus erythematosus (JSLE) is similar to adult-onset SLE, but there are distinct differences in clinical features, serology, and management requirements. It is more aggressive than adult-onset SLE with frequent renal and haematological manifestations and higher mortality rates. The cause of JSLE is unknown but appears to be multifactorial with genetic, immunological, hormonal, and environmental influences. Macrophage activation syndrome is a potentially life-threatening complication, and may mimic the underlying disease or be confused with sepsis. Transferring care from

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Josef, S. M. D. Smolen, and C. C. Zielinski. Systemic Lupus Erythematosus: Clinical and Experimental Aspects. Springer-Verlag, 1987.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

10

1950-, Smolen Josef S., and Zielinski Christoph C. 1952-, eds. Systemic lupus erythematosus: Clinical and experimental aspects. Berlin: Springer-Verlag, 1987.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

11

Condon, Marie, Philippa Dodd, and Liz Lightstone. The patient with systemic lupus erythematosus. Edited by Giuseppe Remuzzi. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199592548.003.0162.

Повний текст джерела

Анотація:

AbstractSystemic lupus erythematosus (SLE) is a chronic, relapsing, inflammatory, often febrile multisystemic disorder, characterized by involvement of the skin, joints, visceral organs, and serosal membranes. Symptoms and manifestations vary widely over an unpredictable relapsing and remitting course.The presentation of SLE can range from mild forms to severe disease requiring hospitalization. Most commonly it manifests as a combination of constitutional symptoms, particularly fatigue and fever, with cutaneous, musculoskeletal, mild haematological, and serological involvement; however, when r

Стилі APA, Harvard, Vancouver, ISO та ін.

12

Tsokos, George. Systemic Lupus Erythematosus: Basic, Applied and Clinical Aspects. Elsevier Science & Technology Books, 2020.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

13

Tsokos, George. Systemic Lupus Erythematosus: Basic, Applied and Clinical Aspects. Elsevier Science & Technology, 2020.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

14

Tsokos, George. Systemic Lupus Erythematosus: Basic, Applied and Clinical Aspects. Elsevier Science & Technology Books, 2016.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

15

Neuropsychiatric Systemic Lupus Erythematosus: Pathogenesis, Clinical Aspects and Treatment. Springer, 2018.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

16

Hirohata, Shunsei. Neuropsychiatric Systemic Lupus Erythematosus: Pathogenesis, Clinical Aspects and Treatment. Springer, 2018.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

17

Turner, Irvine. Systemic Lupus Erythematosus: Risk Factors, Treatment Options and Clinical Aspects. Nova Science Publishers, Incorporated, 2017.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

18

Kammer, Gary M. Lupus: Molecular and Cellular Pathogenesis (Contemporary Immunology). Humana Press, 1999.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

19

Despite Lupus How To Live Well With A Chronic Illness. Booksurge Publishing, 2009.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

20

ABC of Asthma, Allergies and Lupus: Eradicate Asthma - Now! Global Health Solutions, 2000.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

21

Isaacs, Anthony, and David Isenberg. Laboratory tests and investigations. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198739180.003.0005.

Повний текст джерела

Анотація:

In this chapter an overview is provided of the investigations used in patients with systemic lupus erythematosus (SLE); these establish the abnormalities that can be found in each organ/system. Lupus is a very heterogeneous condition, affecting virtually every organ/system. In consequence, numerous investigations and tests are used to help make the diagnosis and define the extent of the organ/system involvement. The chapter is divided into investigations of the effects of SLE on the following systems: haematological, immunological, biochemical, renal, cardiovascular, pulmonary, gastroenterolog

Стилі APA, Harvard, Vancouver, ISO та ін.

22

Berlit, Peter, and Patricia Moore. Vasculitis, Rheumatic Disease and the Nervous System. Springer, 2011.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

23

Peter, Berlit, and Moore P, eds. Vasculitis, rheumatic disease, and the nervous system. Berlin: Springer-Verlag, 1993.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

24

J, Carlson-Newberry Sydne, Southern California Evidence-Based Practice Center/RAND., and United States. Agency for Healthcare Research and Quality., eds. Effects of omega-3 fatty acids on lipids and glycemic control in type II diabetes and the metabolic syndrome and on inflammatory bowel disease, rheumatoid arthritis, renal disease, systemic lupus erythematosus, and osteoporosis. Rockville, MD: Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services, 2004.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

25

Autoimmune Diseases of the Skin: Pathogenesis, Diagnosis, Management. 2nd ed. Springer, 2005.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

26

Hertl, Michael. Autoimmune Diseases of the Skin: Pathogenesis, Diagnosis, Management. Springer, 2011.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

27

Hertl, Michael. Autoimmune Diseases of the Skin: Pathogenesis, Diagnosis, Management. Springer, 2016.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

28

Autoimmune Diseases of the Skin: Pathogenesis, Diagnosis, Management. Springer, 2001.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

29

Strand, Vibeke, Jeremy Sokolove, and Alvina D. Chu. Design of clinical trials in rheumatology. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0030.

Повний текст джерела

Анотація:

Development of new therapies for rheumatic diseases requires a series of randomized controlled trials (RCTs) progressing from phase 1, 'first-in-human' to generate initial safety, pharmacokinetic (PK) and pharmacodynamic (PD) data; to phase 2, proof of concept for efficacy with safety and PK/PD data; and phase 3, designed to demonstrate definitive efficacy and safety to support regulatory approval. Important aspects of RCT designs include sample size estimations, treatment allocation, rescue, blinding, and statistical analyses of prespecified endpoints to preserve trial integrity. Over the pas

Стилі APA, Harvard, Vancouver, ISO та ін.

30

Strand, Vibeke, Jeremy Sokolove, and Alvina D. Chu. Design of clinical trials in rheumatology. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199642489.003.0030_update_001.

Повний текст джерела

Анотація:

Development of new therapies for rheumatic diseases requires a series of randomized controlled trials (RCTs) progressing from phase 1, ’first-in-human’ to generate initial safety, pharmacokinetic (PK) and pharmacodynamic (PD) data; to phase 2, proof of concept for efficacy with safety and PK/PD data; and phase 3, designed to demonstrate definitive efficacy and safety to support regulatory approval. Important aspects of RCT designs include sample size estimations, treatment allocation, rescue, blinding, and statistical analyses of prespecified endpoints to preserve trial integrity. Over the pas

Стилі APA, Harvard, Vancouver, ISO та ін.

31

Strand, Vibeke, Jeremy Sokolove, and Alvina D. Chu. Design of clinical trials in rheumatology. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199642489.003.0030_update_002.

Повний текст джерела

Анотація:

Development of new therapies for rheumatic diseases requires a series of randomized controlled trials (RCTs) progressing from phase 1, ’first-in-human’ to generate initial safety, pharmacokinetic (PK) and pharmacodynamic (PD) data; to phase 2, proof of concept for efficacy with safety and PK/PD data; and phase 3, designed to demonstrate definitive efficacy and safety to support regulatory approval. Important aspects of RCT designs include sample size estimations, treatment allocation, rescue, blinding, and statistical analyses of prespecified endpoints to preserve trial integrity. Over the pas

Стилі APA, Harvard, Vancouver, ISO та ін.

32

Price, Elizabeth J., and Anwar R. Tappuni, eds. Oxford Textbook of Sjögren's Syndrome. Oxford University Press, 2021. http://dx.doi.org/10.1093/med/9780198806684.001.0001.

Повний текст джерела

Анотація:

The Oxford Textbook of Sjögren’s Syndrome is an authoritative textbook, rich with valuable illustrations and figures, providing a practical guide to diagnosing and managing all aspects of this condition. Sjögren’s syndrome is a chronic, immune-mediated condition typically presenting in women in their fifth or sixth decade. With increased awareness and improvement in diagnostic tests, younger women and occasionally men are now being diagnosed with this condition. Frequently, Sjögren’s syndrome occurs in association with other autoimmune diseases, usually rheumatoid arthritis, systemic lupus ery

Стилі APA, Harvard, Vancouver, ISO та ін.

33

Minden, Kirsten. Outcomes of paediatric rheumatic disease. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0035.

Повний текст джерела

Анотація:

Paediatric rheumatic illnesses are among the most common chronic diseases in children and adolescents. These illnesses have important impacts on patient's body functions and structures, activities, and social participation. Knowledge about the effect and consequences of these diseases is necessary to formulate appropriate aims of treatments. The multidimensional outcomes of paediatric rheumatic diseases and their measurement are reviewed in this chapter. Outcome measurement is complex in patients who have growing needs and changing expectations as they develop, especially in chronic conditions

Стилі APA, Harvard, Vancouver, ISO та ін.

34

Minden, Kirsten. Outcomes of paediatric rheumatic disease. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199642489.003.0035_update_002.

Повний текст джерела

Анотація:

Paediatric rheumatic illnesses are among the most common chronic diseases in children and adolescents. These illnesses have important impacts on patient’s body functions and structures, activities, and social participation. Knowledge about the effect and consequences of these diseases is necessary to formulate appropriate aims of treatments. The multidimensional outcomes of paediatric rheumatic diseases and their measurement are reviewed in this chapter. Outcome measurement is complex in patients who have growing needs and changing expectations as they develop, especially in chronic conditions

Стилі APA, Harvard, Vancouver, ISO та ін.

35

Minden, Kirsten. Outcomes of paediatric rheumatic disease. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199642489.003.0035_update_003.

Повний текст джерела

Анотація:

Paediatric rheumatic illnesses are among the most common chronic diseases in children and adolescents. These illnesses have important impacts on patient’s body functions and structures, activities, and social participation. Knowledge about the effect and consequences of these diseases is necessary to formulate appropriate aims of treatments. The multidimensional outcomes of paediatric rheumatic diseases and their measurement are reviewed in this chapter. Outcome measurement is complex in patients who have growing needs and changing expectations as they develop, especially in chronic conditions

Стилі APA, Harvard, Vancouver, ISO та ін.

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!